B3 bx725 genes soc 20181001144639

reVision Therapeutics

Developing treatment for Stargardt Disease which causes blindness in 32K people annually

  • Stage Product In Development
  • Industry Biotechnology
  • Location New York, NY, USA
  • Currency USD
  • Founded October 2018
  • Employees 6
  • Incorporation Type C-corp
  • Website revisiontx.com

Only investors on Gust who have been granted access can view this content.

Interested in this startup? Sign In or Sign Up to request more information.